Publicacións en colaboración con investigadores/as de Hospital Carlos III (37)

2017

  1. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study

    HIV Medicine, Vol. 18, Núm. 7, pp. 482-489

  2. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  2. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

  3. Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in Spain

    AIDS Research and Human Retroviruses, Vol. 30, Núm. 9, pp. 856-862

  4. Very late HCV relapse following triple therapy for hepatitis C

    Antiviral Therapy

  5. X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain

    AIDS, Vol. 28, Núm. 11, pp. 1603-1609

2013

  1. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B

    AIDS, Vol. 27, Núm. 14, pp. 2219-2224

  2. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 9, pp. 1994-2002

  3. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

  4. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir

    Antiviral Therapy, Vol. 18, Núm. 5, pp. 709-715

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  2. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms

    Clinical Infectious Diseases, Vol. 55, Núm. 1

  3. Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain

    Virology Journal, Vol. 9, Núm. 1

2011

  1. Drug resistance mutations in patients infected with HIV-2 living in Spain

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 7, pp. 1484-1488

  2. HTLV infection among foreign pregnant women living in Spain

    Journal of Clinical Virology, Vol. 52, Núm. 2, pp. 119-122

  3. Variabilidad en la determinación del tropismo viral del VIH utilizando diferentes algoritmos genotípicos de interpretación en pacientes VIH-1 infectados con subtipos B versus no-B

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 1, pp. 4-8

2010

  1. Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey

    AIDS Research and Human Retroviruses, Vol. 26, Núm. 8, pp. 861-864